Year Year arrow
arrow-active-down-0
Publisher Publisher arrow
arrow-active-down-1
Journal
1
Journal arrow
arrow-active-down-2
Institution Institution arrow
arrow-active-down-3
Institution Country Institution Country arrow
arrow-active-down-4
Publication Type Publication Type arrow
arrow-active-down-5
Field Of Study Field Of Study arrow
arrow-active-down-6
Topics Topics arrow
arrow-active-down-7
Open Access Open Access arrow
arrow-active-down-8
Language Language arrow
arrow-active-down-9
Filter Icon Filter 1
Year Year arrow
arrow-active-down-0
Publisher Publisher arrow
arrow-active-down-1
Journal
1
Journal arrow
arrow-active-down-2
Institution Institution arrow
arrow-active-down-3
Institution Country Institution Country arrow
arrow-active-down-4
Publication Type Publication Type arrow
arrow-active-down-5
Field Of Study Field Of Study arrow
arrow-active-down-6
Topics Topics arrow
arrow-active-down-7
Open Access Open Access arrow
arrow-active-down-8
Language Language arrow
arrow-active-down-9
Filter Icon Filter 1
Export
Sort by: Relevance
  • Research Article
  • 10.1016/bs.apha.2024.10.018
Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function
  • Jan 1, 2025
  • Advances in Pharmacology
  • Robyn Wiseman + 3 more

  • Research Article
  • Cite Count Icon 1
  • 10.1016/bs.apha.2024.10.004
Biological and therapeutic significance of targeting NLRP3 inflammasome in the brain and the current efforts to develop brain-penetrant inhibitors
  • Jan 1, 2025
  • Advances in Pharmacology
  • Baljit Kaur + 5 more

  • Research Article
  • 10.1016/bs.apha.2024.10.016
Evolution of D-amino acid oxidase inhibitors: From concept to clinic
  • Jan 1, 2025
  • Advances in Pharmacology
  • Ayush Bajaj + 1 more

  • Research Article
  • 10.1016/bs.apha.2024.10.017
Drug discovery strategy for TAK-418, a specific inhibitor of LSD1 enzyme activity, as a novel therapy for autism
  • Oct 29, 2024
  • Advances in Pharmacology
  • Satoru Matsuda + 2 more

  • Research Article
  • Cite Count Icon 2
  • 10.1016/bs.apha.2024.10.015
Neutral sphingomyelinase 2: A promising drug target for CNS disease
  • Oct 28, 2024
  • Advances in Pharmacology
  • Meixiang Huang + 7 more

  • Research Article
  • 10.1016/bs.apha.2024.10.012
Chapter Two - Anti-fibrotics in inflammatory bowel diseases: Challenges and successes
  • Jan 1, 2024
  • Advances in Pharmacology
  • Gaurav Chauhan + 3 more

  • Research Article
  • 10.1016/bs.apha.2024.10.009
Chapter Four - AXL: A novel therapeutic target in IBD
  • Jan 1, 2024
  • Advances in Pharmacology
  • Bejan J Saeedi + 3 more

  • Research Article
  • 10.1016/bs.apha.2024.10.010
Chapter Eleven - The potential of targeting TREM-1 in IBD
  • Jan 1, 2024
  • Advances in Pharmacology
  • Emilie Vinolo + 6 more

  • Research Article
  • 10.1016/bs.apha.2024.10.001
Chapter Nine - Targeting glutamate carboxypeptidase II in IBD
  • Jan 1, 2024
  • Advances in Pharmacology
  • Diane E Peters

  • Research Article
  • 10.1016/bs.apha.2024.09.001
Chapter Three - Emerging therapeutics for the management of intestinal fibrosis and strictures
  • Jan 1, 2024
  • Advances in Pharmacology
  • Yub Raj Neupane + 4 more